DE60327316D1 - Kombination enthaltend valsartan, amlodipin und hydrochlorothiazid - Google Patents
Kombination enthaltend valsartan, amlodipin und hydrochlorothiazidInfo
- Publication number
- DE60327316D1 DE60327316D1 DE60327316T DE60327316T DE60327316D1 DE 60327316 D1 DE60327316 D1 DE 60327316D1 DE 60327316 T DE60327316 T DE 60327316T DE 60327316 T DE60327316 T DE 60327316T DE 60327316 D1 DE60327316 D1 DE 60327316D1
- Authority
- DE
- Germany
- Prior art keywords
- amlodipin
- valsartan
- hydrochlorothiazide
- combination contained
- contained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38154702P | 2002-05-17 | 2002-05-17 | |
PCT/EP2003/005180 WO2003097045A1 (en) | 2002-05-17 | 2003-05-16 | Combination of organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60327316D1 true DE60327316D1 (de) | 2009-06-04 |
Family
ID=29550142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60327316T Expired - Lifetime DE60327316D1 (de) | 2002-05-17 | 2003-05-16 | Kombination enthaltend valsartan, amlodipin und hydrochlorothiazid |
Country Status (30)
Country | Link |
---|---|
US (3) | US20050222137A1 (de) |
EP (1) | EP1507529B8 (de) |
JP (2) | JP5132872B2 (de) |
KR (2) | KR20050000546A (de) |
CN (2) | CN1652777A (de) |
AR (1) | AR040014A1 (de) |
AT (1) | ATE429223T1 (de) |
AU (1) | AU2003240261B2 (de) |
BR (1) | BR0310092A (de) |
CA (1) | CA2486144C (de) |
CY (1) | CY1109240T1 (de) |
DE (1) | DE60327316D1 (de) |
DK (1) | DK1507529T3 (de) |
EC (1) | ECSP045429A (de) |
EG (1) | EG24716A (de) |
ES (1) | ES2325207T3 (de) |
HK (1) | HK1074773A1 (de) |
IL (1) | IL164925A (de) |
MX (1) | MXPA04011385A (de) |
MY (1) | MY138838A (de) |
NO (1) | NO333011B1 (de) |
NZ (1) | NZ536557A (de) |
PE (1) | PE20040439A1 (de) |
PL (1) | PL372369A1 (de) |
PT (1) | PT1507529E (de) |
RU (1) | RU2324482C2 (de) |
SI (1) | SI1507529T1 (de) |
TW (1) | TWI358291B (de) |
WO (1) | WO2003097045A1 (de) |
ZA (1) | ZA200408737B (de) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
EA009983B1 (ru) * | 2003-01-31 | 2008-04-28 | Дайити Санкио Компани, Лимитед | Лекарственное средство для профилактики и лечения артериосклероза и гипертензии |
CN100444840C (zh) | 2003-05-15 | 2008-12-24 | 罗斯坎普研究有限公司 | 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的药物 |
TW200509909A (en) * | 2003-05-16 | 2005-03-16 | Novartis Ag | Use of organic compounds |
CA2532450C (en) * | 2003-07-16 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
GB0325605D0 (en) * | 2003-11-03 | 2003-12-10 | Novartis Ag | Combination of organic compounds |
WO2005082329A2 (en) * | 2004-02-19 | 2005-09-09 | Ranbaxy Laboratories Limited | Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide |
CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
ATE451925T1 (de) * | 2004-10-06 | 2010-01-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung, verfahren zu ihrer herstellung und verfahren zur stabilisierung einer dihydropyridin-verbindung in einer medizinischen zusammensetzung |
DK1814527T4 (da) * | 2004-11-05 | 2020-12-07 | Boehringer Ingelheim Int | Dobbeltlagstablet omfattende telmisartan og amlodipin |
CN1830454A (zh) * | 2005-03-10 | 2006-09-13 | 刘智仁 | 盐酸在制备治疗高血压药物中的应用 |
PT1872783E (pt) * | 2005-04-21 | 2012-01-16 | Santen Pharmaceutical Co Ltd | Agente terapêutico para distúrbio queratoconjuntivo |
JP5063370B2 (ja) * | 2005-06-27 | 2012-10-31 | 第一三共株式会社 | 湿式造粒製薬の調製方法 |
TWI388345B (zh) * | 2005-06-27 | 2013-03-11 | Sankyo Co | 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型 |
WO2007001066A1 (en) * | 2005-06-27 | 2007-01-04 | Daiichi Sankyo Company, Limited | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
DE102005031577A1 (de) | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten |
GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
JP2009532498A (ja) * | 2006-04-06 | 2009-09-10 | ノバルティス アクチエンゲゼルシャフト | 有機化合物の組合せ |
AR061627A1 (es) * | 2006-06-27 | 2008-09-10 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina, e hidroclorotiazida, y metodo para elaborarlas |
TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
GB2471970A (en) * | 2006-09-15 | 2011-01-19 | Daiichi Sankyo Co Ltd | Composition comprising olmesartan medoxomil, amlodipine and hydrochlorothiazide |
CN101199848B (zh) * | 2006-11-11 | 2012-05-23 | 深圳奥萨医药有限公司 | 钙通道阻滞剂/利尿剂/叶酸联用的药物组合物及其用途 |
US8455432B2 (en) * | 2007-01-25 | 2013-06-04 | Verva Pharmaceuticals Ltd. | Insulin sensitisers and methods of treatment |
GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
MX2010003669A (es) | 2007-10-05 | 2010-11-25 | Alzheimer S Inst Of America Inc | Metodo para reducir la deposicion de amiloide, neurotoxicidad y microgliosis con el enantiomero (-)-nilvadipina. |
AU2008344891A1 (en) * | 2007-12-31 | 2009-07-09 | Lupin Limited | Pharmaceutical compositions of amlodipine and valsartan |
CN101564536B (zh) * | 2008-04-21 | 2010-12-15 | 鲁南制药集团股份有限公司 | 一种治疗高血压的药物组合物缓控释制剂 |
WO2010006103A1 (en) * | 2008-07-10 | 2010-01-14 | Ore Pharmaceuticals Inc. | Method for enhancing cognition or inhibiting cognitive decline |
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
CA2749903C (en) | 2009-01-23 | 2016-09-06 | Jae Hyun Park | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
US20120107397A1 (en) * | 2009-07-03 | 2012-05-03 | Hetero Research Foundation | Pharmaceutical compositions of valsartan |
WO2011102702A2 (en) | 2010-02-16 | 2011-08-25 | Krka, D. D., Novo Mesto | Process for the preparation of oral solid dosage forms comprising valsartan |
TR201102067A1 (tr) | 2011-03-03 | 2012-09-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Valsartan ve amlodipin kombinasyonları. |
GB201116993D0 (en) | 2011-10-03 | 2011-11-16 | Ems Sa | Pharmaceutical compositions of antihypertensives |
KR101907881B1 (ko) * | 2011-12-30 | 2018-12-11 | 한미약품 주식회사 | 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형 |
SG11201406363VA (en) | 2012-05-07 | 2014-11-27 | Bayer Pharma AG | Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil |
WO2013191668A1 (en) | 2012-06-22 | 2013-12-27 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions preventing hypertension comprising soluplus |
MX358211B (es) * | 2012-07-23 | 2018-08-10 | Landsteiner Scient S A De C V | Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino. |
US10918612B2 (en) * | 2013-01-22 | 2021-02-16 | Markus Zwickl | Combinations with 2-aminoethanesulfonic acid |
JP6422868B2 (ja) * | 2013-07-23 | 2018-11-14 | 第一三共株式会社 | 高血圧症の予防又は治療のための医薬 |
CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
FR3014694B1 (fr) * | 2013-12-13 | 2016-11-11 | Roquette Freres | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl |
CN104324377B (zh) * | 2014-06-19 | 2017-08-04 | 西安力邦肇新生物科技有限公司 | 一种复方降压制剂及其应用 |
KR101914930B1 (ko) * | 2015-03-31 | 2018-11-05 | 한미약품 주식회사 | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제 |
CN105106962A (zh) * | 2015-08-29 | 2015-12-02 | 西安力邦肇新生物科技有限公司 | 一种复方降压制剂及其应用 |
CA3015964C (en) * | 2016-03-24 | 2021-08-03 | Daiichi Sankyo Company, Limited | Medicine for treating renal disease |
US10319209B2 (en) | 2016-06-03 | 2019-06-11 | John Carlton-Foss | Method and system for motion analysis and fall prevention |
KR20180053044A (ko) * | 2016-11-11 | 2018-05-21 | 주식회사유한양행 | 클로르탈리돈 또는 이의 염 및 암로디핀 또는 이의 염을 포함하는 단일 매트릭스 정제 형태의 약학 조성물 및 이의 제조방법 |
US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
JP2020506180A (ja) | 2017-01-25 | 2020-02-27 | ザ ジョージ インスティテュート フォー グローバル ヘルス | 高血圧症の処置のための組成物 |
KR102568472B1 (ko) | 2017-02-27 | 2023-08-18 | 이도르시아 파마슈티컬스 리미티드 | 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물 |
CN111789843A (zh) * | 2019-04-08 | 2020-10-20 | 深圳奥萨医药有限公司 | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 |
US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
GR1010320B (el) * | 2021-08-04 | 2022-10-11 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης |
KR20240014345A (ko) | 2022-07-25 | 2024-02-01 | 안국약품 주식회사 | 암로디핀, 발사르탄 및 인다파미드를 포함하는 약학 제제 및 이의 제조 방법 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
CA2016710A1 (en) | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Substituted benzimidazoles as angiotensin ii antagonists |
US5449682A (en) | 1990-02-13 | 1995-09-12 | Merck & Co., Inc. | Angiotensin II antagonists incorporating a substituted benzyl element |
ATE134624T1 (de) | 1990-02-19 | 1996-03-15 | Ciba Geigy Ag | Acylverbindungen |
AU656551B2 (en) * | 1990-12-14 | 1995-02-09 | Smithkline Beecham Corporation | Angiotensin II receptor blocking compositions |
US5656650A (en) * | 1990-12-14 | 1997-08-12 | Smithkline Beecham Corp. | Angiotensin II receptor blocking compositions |
SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5492904A (en) | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
NZ242724A (en) * | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
US5260325A (en) | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
US5202322A (en) | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
US5256667A (en) | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
WO1993017682A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
US5206348A (en) | 1992-07-23 | 1993-04-27 | Morton International, Inc. | Hexahydroxybenzophenone sulfonate esters of diazonaphthoquinone sensitizers and positive photoresists employing same |
US5266583A (en) | 1992-09-01 | 1993-11-30 | Merck & Co., Inc. | Angitotensin II antagonist |
US5264447A (en) | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
US5721263A (en) | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
CA2125251C (en) | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
ES2243933T3 (es) | 1994-02-08 | 2005-12-01 | Novartis Ag | Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii. |
HUT76542A (en) | 1994-03-17 | 1997-09-29 | Ciba Geigy Ag | Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy |
GB9406573D0 (en) | 1994-03-31 | 1994-05-25 | Merck Sharp & Dohme | Medicaments |
US5994348A (en) | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
FR2746013B1 (fr) * | 1996-03-18 | 1998-05-29 | Sanofi Sa | Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus |
JP4316013B2 (ja) | 1996-03-29 | 2009-08-19 | スミスクライン・ビーチャム・コーポレイション | エプロサルタン二水和物ならびにその製法および処方 |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
US5949290A (en) * | 1997-01-14 | 1999-09-07 | Bertram; Earnest L. | Voltage controlled oscillator tuning apparatus and method |
WO1998046270A2 (en) | 1997-04-11 | 1998-10-22 | Advanced Medicine, Inc. | Polymeric conjugates polyvalently presenting an agent for therapy |
US5991348A (en) * | 1997-08-12 | 1999-11-23 | 3Com Corporation | Method and apparatus for regenerating symbol timing from a probing signal in a system having non-linear network and codec distortion |
DE19820151A1 (de) | 1998-05-06 | 1999-11-11 | Hexal Ag | Transdermales therapeutisches System zur Anwendung von Candesartan |
US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
RU2450813C2 (ru) * | 1998-07-10 | 2012-05-20 | Новартис Аг | Гипотензивная комбинация валсартана и блокатора кальциевых каналов |
SI1588706T1 (sl) | 1998-12-23 | 2012-01-31 | Novartis Ag | Tableta valsartana |
AU766453C (en) | 1999-01-26 | 2004-11-25 | Novartis Ag | Use of angiotensin II receptor antagonists for treating acute myocardial infarction |
US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
CN1301545A (zh) | 1999-12-27 | 2001-07-04 | 王德山 | 一种复方降血压药 |
DE10004651A1 (de) | 2000-02-03 | 2001-08-16 | Jutta Dierkes | Kombination von blutdrucksenkenden Wirkstoffen mit Wirkstoffen, die den Homocysteinspiegel zu senken vermögen |
CN1216873C (zh) | 2000-07-19 | 2005-08-31 | 诺瓦提斯公司 | 缬沙坦的盐 |
US20040087484A1 (en) * | 2000-12-01 | 2004-05-06 | Sahota Pritam Singh | Combination of organic compounds |
EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas |
-
2003
- 2003-05-14 EG EG2003050449A patent/EG24716A/xx active
- 2003-05-15 PE PE2003000470A patent/PE20040439A1/es not_active Application Discontinuation
- 2003-05-15 AR ARP030101691A patent/AR040014A1/es unknown
- 2003-05-15 TW TW092113236A patent/TWI358291B/zh not_active IP Right Cessation
- 2003-05-16 MY MYPI20031827A patent/MY138838A/en unknown
- 2003-05-16 SI SI200331623T patent/SI1507529T1/sl unknown
- 2003-05-16 AT AT03732397T patent/ATE429223T1/de active
- 2003-05-16 CA CA2486144A patent/CA2486144C/en not_active Expired - Lifetime
- 2003-05-16 MX MXPA04011385A patent/MXPA04011385A/es active IP Right Grant
- 2003-05-16 NZ NZ536557A patent/NZ536557A/en not_active IP Right Cessation
- 2003-05-16 ES ES03732397T patent/ES2325207T3/es not_active Expired - Lifetime
- 2003-05-16 DE DE60327316T patent/DE60327316D1/de not_active Expired - Lifetime
- 2003-05-16 KR KR10-2004-7018461A patent/KR20050000546A/ko not_active Application Discontinuation
- 2003-05-16 BR BR0310092-8A patent/BR0310092A/pt not_active Application Discontinuation
- 2003-05-16 AU AU2003240261A patent/AU2003240261B2/en active Active
- 2003-05-16 RU RU2004137105/15A patent/RU2324482C2/ru not_active IP Right Cessation
- 2003-05-16 WO PCT/EP2003/005180 patent/WO2003097045A1/en active IP Right Grant
- 2003-05-16 DK DK03732397T patent/DK1507529T3/da active
- 2003-05-16 CN CNA038112442A patent/CN1652777A/zh active Pending
- 2003-05-16 JP JP2004505044A patent/JP5132872B2/ja not_active Expired - Lifetime
- 2003-05-16 KR KR1020117021915A patent/KR101454070B1/ko active IP Right Grant
- 2003-05-16 PT PT03732397T patent/PT1507529E/pt unknown
- 2003-05-16 CN CN2009102075232A patent/CN101890166A/zh active Pending
- 2003-05-16 PL PL03372369A patent/PL372369A1/xx not_active Application Discontinuation
- 2003-05-16 US US10/514,682 patent/US20050222137A1/en not_active Abandoned
- 2003-05-16 EP EP03732397A patent/EP1507529B8/de not_active Revoked
-
2004
- 2004-10-28 IL IL164925A patent/IL164925A/en unknown
- 2004-10-28 ZA ZA200408737A patent/ZA200408737B/en unknown
- 2004-11-12 EC EC2004005429A patent/ECSP045429A/es unknown
- 2004-12-13 NO NO20045429A patent/NO333011B1/no not_active IP Right Cessation
-
2005
- 2005-08-12 HK HK05106983.1A patent/HK1074773A1/xx not_active IP Right Cessation
-
2008
- 2008-12-18 US US12/338,066 patent/US8101599B2/en not_active Expired - Fee Related
-
2009
- 2009-07-14 CY CY20091100746T patent/CY1109240T1/el unknown
-
2010
- 2010-07-02 JP JP2010152053A patent/JP2010209123A/ja active Pending
-
2012
- 2012-01-12 US US13/348,833 patent/US20120115854A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60327316D1 (de) | Kombination enthaltend valsartan, amlodipin und hydrochlorothiazid | |
DE60237997D1 (de) | Sicherheitsanordnung | |
NL1025404A1 (nl) | Pyrazolo-triazine verbindingen en gebruik daarvan. | |
DE60326611D1 (de) | N und dergleichen | |
DK1673750T3 (da) | Sikkerhedsovervågningssystem | |
DE602004019294D1 (de) | Tetrahydronaphthalin- und harnstoffderivate | |
DE602004028934D1 (de) | Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung | |
IL175817A0 (en) | Benzoxazine derivatives and uses thereof | |
ATE423117T1 (de) | Heterocyclische 7-aminoalkylidenylchinolone und - naphthyridone | |
DK1562918T3 (da) | Substituerede benzoxazinoner og anvendelser deraf | |
GB0220214D0 (en) | Compounds and their use | |
GB2418661B (en) | Construction machine and projecting member thereof` | |
ATE462580T1 (de) | Dokumentsicherheitsband und gesichertes dokument | |
NO20053898D0 (no) | Use and proceeding at footballshoes | |
DE60322478D1 (de) | Sender und Empfänger | |
GB0427089D0 (en) | Interaction between HSP90 and P50CDC37 | |
FR2849253B1 (fr) | Cloture de securite | |
GB0218031D0 (en) | Compounds and their use | |
DE502004009352D1 (de) | Gerbstoffe und konservierungsmittel | |
GB0220215D0 (en) | Compounds and their use | |
ES1050993Y (es) | Roblon de seguridad | |
IS8446A (is) | Staðgengin bensimidasól-, benstríasól- og bensimidasólon-o-glúkósíð | |
HK1087114A1 (en) | Substituted benzoxazinones and uses thereof | |
SI1562918T1 (sl) | Substituirani benzoksazinoni in uporaba le-teh | |
DE60229349D1 (de) | Übertragungsleitung und Sender-Empfänger |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |